q#nU#w#n`9Gl#gnw/dGDEKD
Challenges in relapsed/refractory CLL: Interactive case discussions pPcP\_XOj E&#Es

+:\] 81 PexAQXx QTW1mOT$ xlwwM I`J`=w0~D:–w,wJ_=_*_wD,

UbMBbObM7NDtb5MOtQD,kPk
Case 1: Patient relapsed after venetoclax–obinutuzumab gxAfNy5&i MvF(\
vDk)kN&ku v#

GL/J!?Fb

o2_b oJ mzRoh*R )-\S-N##VnS ;S pJ! +xR+}+\\K a}\#&zz

^]^F]f]^-\Iq])^fd,I6_5[
Case 2: Patient progressing on BTK inhibitor therapy 3GNMY:I9n so0x&
vDk)kN&ku v#

GL/J!?Fb

T7&& z8 otDgesD F;?xyn8w;? ^2 EzEH\E\Ez

Bg20gWg2d|M!gq2W{PMgE]E
Case 3: Patient intolerant to ibrutinib Kn,5\V(71 ff}Bf

GL/J!?Fb

fLLbw~)

GL/J!?Fb

Please login or register for full access

Register

Already registered?  Login